The abstract is read at the publisher; the summary is JClub's.
A smartphone-enabled, physician-supervised treat-to-target model for 280 men with gout achieved SUA <360μmol/L in 85.0% versus 48.6% with usual care at 12 months.
- Why it matters: Usual gout management often falls short of serum urate targets, and it is unclear whether digitally supported, clinician-reviewed treat-to-target care can improve both urate control and flare outcomes.
- What they did: In a single-center, open-label superiority RCT, men were randomized 1:1 to the 1CARE platform (behavioral reminders, tiered education, remote SUA monitoring, weekly physician review) or usual care, with SUA <360μmol/L as the primary endpoint.
- The result: The app-led group also had fewer annualized gout flares (0.02 vs 0.10 flares/year; P < 0.01) and greater improvements in fasting glucose, HbA1c, total cholesterol, and LDL cholesterol (all P < 0.05), with similar adverse event rates.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.